Company news

Chemical Works of Gedeon Richter PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Chemical Works of Gedeon Richter: Richter receives FDA Submission Acceptance of New Drug Application for FYLREVY in the U.S.

October 14, 2026

Richter receives FDA Submission Acceptance of New Drug Application for FYLREVY® in the U.S.

October 14, 2026

Transactions with Treasury Shares

October 8, 2026

Transactions with Treasury Shares

October 2, 2026

Voting rights, registered capital

September 30, 2026

Voting rights, registered capital

September 30, 2026

Notification on change in voting rights

September 4, 2026

Voting rights, registered capital

August 31, 2026

Transactions with Treasury Shares

August 28, 2026

Half-yearly Report 2026 H1

August 6, 2026

Richter and Adalvo Expand Global Co-Development Partnership in Tirzepatide Across Diabetes and Obesity Care

August 6, 2026

Bond interest payment

July 10, 2026

Chemical Works of Gedeon Richter: Richter and Hetero Announce Global Cooperation for the Development and Commercialization of Semaglutide Injection (Generic of Ozempic®)

June 10, 2026

Richter and Acrux agree to license Lenzetto® for Australia

May 27, 2026

Transactions with Treasury Shares

May 14, 2026

Interim management statement

May 12, 2026

Chemical Works of Gedeon Richter: Richter publishes Q1 2026 results

May 12, 2026

Chemical Works of Gedeon Richter: Richter receives European Commission approval for Tuyory®, its biosimilar tocilizumab in multiple indications

April 29, 2026

Chemical Works of Gedeon Richter: Consolidated Financial Statements 2025 - Independent Auditor’s Report

April 7, 2026

Separate Financial Statements 2025- Independent Auditor’s Report

April 7, 2026

Calls

Decks

The 5 newest of 42 decks. Every deck is listed under its year.